Navigation Links
NeurogesX Reports First Quarter 2011 Results
Date:4/29/2011

grew to 60% of all institutional customers ordering in the first quarter 2011, up from 46% in fourth quarter 2010
  • The cumulative number of  private physician customers that have ordered Qutenza rose to 221 through March 31, 2011, up from 159 at December 31, 2010
  • Training activity continues with 1,535 physicians and institutions trained by March 31, 2011, up from 1,127 at December 31, 2010

  • First Quarter 2011 ResultsTotal revenue for the first quarter ended March 31, 2011 was $3.2 million, which consisted of $2.6 million in collaboration revenue, primarily from the amortization of upfront license fees received under the Astellas Agreement, and $0.6 million of Qutenza product sales.  

    During the three months ended March 31, 2011, the Company recorded sales of Qutenza to its specialty distribution and specialty pharmacy customers totaling $0.6 million. Under the Company's revenue recognition policy, the Company recognized revenue during the three months ended March 31, 2011 totaling $0.6 million.  

    Due to the limited history of product returns and cash collections, NeurogesX recognizes revenue at the later of the time the product is shipped by its customers to healthcare professionals and the date of cash collection.  As of March 31, 2011, the Company had $0.6 million of deferred product revenue.  Deferred revenue is reported net of associated cost of goods sold on the Company's balance sheet. Of the deferred revenue total, $0.4 million was sold through to end users (i.e., physicians, clinics and hospitals) and the deferral resulted from cash payments not yet being due under the payment terms, while $0.2 million represented deferral of sales into the Company's distribution channel, recognition of which will be based ultimately upon sales of those units to end users.

    Cost of goods sold for the first quarter 2011 totaled $0.1 million. Cost of goods sold includes product costs, fixed monthly cha
    '/>"/>

    SOURCE NeurogesX, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
    2. NeurogesX Reports Fourth Quarter and Year-End 2010 Results
    3. NeurogesX to Provide Qutenza® Launch Update
    4. NeurogesX to Present at Two February Investor Conferences
    5. NeurogesX Receives Qutenza®-Specific J-Code From Centers for Medicare and Medicaid Services (CMS)
    6. NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
    7. NeurogesX to Hold Conference Call to Discuss Third Quarter 2010 Results
    8. NeurogesX to Present at Oppenheimer & Co Healthcare Conference
    9. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
    10. NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
    11. NeurogesX Receives FDA Approval of Qutenza(TM) (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/1/2015)... ATLANTA , March 1, 2015  An ... offer chronic migraine sufferers sustained relief of their ... Society of Interventional Radiology ,s Annual ... and the State University New York Empire State ... image-guided, intranasal sphenopalatine ganglion (SPG) blocks to give ...
    (Date:2/27/2015)... Feb. 27, 2015 Roughly three-quarters of ... confident substituting an interchangeable biosimilar for its branded ... same nonproprietary name, according to a survey published ... Journal of Managed Care & Specialty Pharmacy ... percent of pharmacists would feel as confident if ...
    (Date:2/27/2015)... -- WuXi PharmaTech (Cayman) Inc. (NYSE:  WX), a leading ... pharmaceutical, biotechnology, and medical device industries with operations in ... United States , congratulates our partner TaiMed Biologics ... for ibalizumab (TMB355). The FDA designates a drug as ... in combination with one or more other drugs, to ...
    Breaking Medicine Technology:Image-guided treatment shown to break the migraine cycle 2Image-guided treatment shown to break the migraine cycle 3Image-guided treatment shown to break the migraine cycle 4Survey Published in AMCP's JMCP Finds Pharmacists Are Most Confident Substituting Interchangeable Biosimilars for Brand Biologics When Products Share Nonproprietary Name 2WuXi Congratulates TaiMed Biologics on Receiving Breakthrough Therapy Designation from U.S. FDA 2
    ... First Commercial Market to Demonstrate Test,s Potential for ... ... ASA (OSL: DIAG) and Applied Biosystems Inc. (NYSE: ABI ) today,announced ... The test searches for a unique gene expression signature,identified by DiaGenic using ...
    ... Drug was Well-Tolerated, Significantly Inhibited ... on Monday, November 10 at 8:30 ... a.m. ET-, ... VIAP ), a biotechnology company focused on,the development of compounds for the treatment ...
    Cached Medicine Technology:Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test 2Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test 3VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 2VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 3VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 4VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 5VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 6VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 7VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 8
    (Date:3/1/2015)... CrossFit Attollo is a CrossFit gym located in Vancouver Washington. ... new members. Now through the end of March new ... receive their fourth month half off. , Paying ... three month contract is only $264, dropping the price down ... in at only $55. The special saves new members $121 ...
    (Date:2/28/2015)... In a recent episode of ... Game Change Athlete Development Services and Consultancy talks ... of athlete development and player engagement during and after ... that athletes face and how off-field activities are a ... became involved in athlete development issues while in graduate ...
    (Date:2/28/2015)... 2015 The Classic Denture Center ... new special. Throughout all of March patients can ... This service can help overall mouth health ... Patients may notice certain symptoms that suggest the denture ... symptoms include: , 1.    Pain, clicking, and popping in the ...
    (Date:2/28/2015)... Indosoft Inc , developers of Q-Suite, a ... to announce the development of Q-Suite 5.9. Building off ... Q-Suite, this new version will include enhancements to existing ... to the leading edge call center software. General availability ... features to enhance security and protection. Administrators will be ...
    (Date:2/28/2015)... February 28, 2015 Pioneer Millworks reclaimed ... Japan Architecture & Construction Materials Show, an annual, premier ... than 1,000 suppliers and top manufacturers of the latest ... wood products sourced and manufactured by Pioneer Millworks ... popularity in Japan at restaurants, hotels, retailers, and corporate ...
    Breaking Medicine News(10 mins):Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2
    ... Better interventions could prevent trapped fingers in doors, expert says ... amputations accounted for almost two-thirds of all pediatric amputations due ... study shows. , In total, the researchers found that there ... aged 17 and younger that year. In children aged 4 ...
    ... Studies of retinal differences in birds could lead to treatments ... -- Chickens and other birds have a better ability to ... scientists mapped five types of light receptors in the chicken,s ... patterns that maximize the bird,s ability to see many colors ...
    ... ... ... ... ...
    ... URBANA -- Farmers, markets are not created equal. Some ... wide variety of vendors. And each market,s unique personality attracts ... revealed that based on what they offer, farmers, markets self-select ... other retail stores isn,t one of them. "Not one ...
    ... ... ... ... WASHINGTON , Feb. 19 Speaker Nancy Pelosi released the following statement in response to ...
    ... ... ... , , ... ...
    Cached Medicine News:Health News:Traumatic Amputations in Children Have High Costs 2Health News:Chickens May Provide Clues to Color Vision 2Health News:Fraud, Racketeering Action Filed Against Dahn Yoga 2Health News:Fraud, Racketeering Action Filed Against Dahn Yoga 3Health News:Fraud, Racketeering Action Filed Against Dahn Yoga 4Health News:Fraud, Racketeering Action Filed Against Dahn Yoga 5Health News:Farmers' markets offer different strokes for different folks 2Health News:Farmers' markets offer different strokes for different folks 3Health News:Pelosi Statement on Additional Aid to States In Medicare Part D Payments 2Health News:Massachusetts Hospital Agrees to Pay U.S. $2.79 Million to Resolve False Claims Act Allegations 2
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    Medicine Products: